| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6028071 | ACROTECH BIOPHARMA | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul, 2022
(1 year, 9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7622470 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(1 year, 1 month from now) | |
| US8299078 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(1 year, 1 month from now) | |
Folotyn is owned by Acrotech Biopharma.
Folotyn contains Pralatrexate.
Folotyn has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Folotyn are:
- US6028071
Folotyn was authorised for market use on 24 September, 2009.
Folotyn is available in solution;intravenous dosage forms.
Folotyn can be used as treatment of patients with relapsed or refractory peripheral t-cell lymphoma.
Drug patent challenges can be filed against Folotyn from 24 September, 2013.
The generics of Folotyn are possible to be released after 31 May, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 24, 2016 |
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2014 |
Drugs and Companies using PRALATREXATE ingredient
NCE-1 date: 24 September, 2013
Market Authorisation Date: 24 September, 2009
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
Dosage: SOLUTION;INTRAVENOUS
FOLOTYN family patents
